Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.15M
Market Cap
$368.46M
Enterprise Value$736.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.02
Next Earnings
Mar 04, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding197,035,170
10 Day Avg. Volume2,210,226
30 Day Avg. Volume4,151,030
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.08
Enterprise Value/Ebitda-25.53
Forecast
1Y Price Target
$6.76Price Target Upside265.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesEsperion presented additional exploratory data demonstrating the impact of bempedoic acid on reducing major adverse limb events in patients with peripheral artery disease.
Global ExpansionBDA is expected to expand globally as a preferred therapy for lipid and cardiovascular risk management.
Market AdoptionThe reduction in major adverse limb events could potentially support the adoption of bempedoic acid by the physician community.
Bears Say
Market AwarenessUncertainties remain despite expanding awareness of bempedoic acid.
Market RisksThe risk/reward profile of shares is viewed as skewed to the downside relative to other opportunities.
Sales ForecastThe U.S. sales projection is lowered from $286MM to approximately $196MM, aligning with the consensus estimate.
---
Ownership Overview
0.99% Insiders
18.47% Mutual Funds
27.56% Other Institutional Investors
43.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $1.58 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $368.46M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Mar 04, 2025 which is in 10 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.025.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.13.
How many shares outstanding does Esperion have?
Esperion has 197,035,170 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -4.525%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
---
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.76 (265.41% Upside)
$6.76 (265.41% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $44.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.97%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Esperion has shown strong prescription growth and expanded payer access, both domestically and internationally. While facing some financial headwinds due to contract updates, the company is on track for future growth with a strengthened financial position.Read More>---
ESPR Stock 12 Month Forecast
Average Price Target
$6.76
▲(265.41% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
9/24 ratings generated profit
1 Year Average Return
+38.42%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +38.42% per trade.
---